Neurocrine Biosciences has agreed to acquire Soleno Therapeutics for $2.9 billion, the companies said, in a deal designed to bolster the buyer’s portfolio of marketed endocrinology and rare disease ...

Gilead Sciences has agreed to acquire German-based Tubulis for up to $5 billion, the companies said today, in a deal designed to expand the buyer’s antibody–drug conjugate (ADC) capabilities with a ...

A new class of drug compounds, called ENDOtollins, reduce harmful inflammation while maintaining the body’s ability to fight infections.

Microplastics turned up in every human bile sample tested and pushed duct cells toward mitochondrial dysfunction and ...

A new metabolic mechanism describes how tumors disable “gatekeeper” cells to prevent immune response to cancer.

Researchers suggest their approach has the potential to transform early disease detection and health monitoring across diverse clinical settings.

The integrated approach is designed to adapt to the evolving needs of new therapeutic modalities, delivering both speed and performance.

Directly transferring healthy mitochondria or cytoplasmic components into target cells is particularly relevant for regenerative medicine.

Microgels mimic the mechanical properties of natural platelets to maximize the ability of the B peptides to create fibrin ...

These pillars are composed of polyacrylamide hydrogel, a material whose stiffness can be adjusted to match the ~5 kPa ...

Combination therapy led to complete remission in more than 50% of mice with different tumor types, many of which were resistant to ICB therapy alone.

The data shows when the protein is removed from neurons or has its signaling activity blocked with drugs, axonal fibers grew more effectively.